Basic Information
| LncRNA/CircRNA Name | GAPLINC |
| Synonyms | NA |
| Region | GRCh38_18:3466250-3478978 |
| Ensemble | ENSG00000266835 |
| Refseq | NR_110429 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioblastoma multiforme |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP, etc. |
| Sample | GBM cell lines (T98G, U251, LN18, LN229, and A172) |
| Expression Pattern | up-regulated |
| Function Description | GAPLINC expression was significantly up-regulated in both GBM tissues and cell lines. The overexpression of GAPLINC was associated with shorter overall survival and disease-free survival. Functional assays indicated that GAPLINC silencing suppressed GBM cells proliferation, migration, and invasion, and promoted apoptosis. In the mechanism, we found that GAPLINC acted as a competing endogenous RNA to sponge miR-331-3p and knockdown of GAPLINC promoted the expression of miR-331-3p. |
| Pubmed ID | 30657584 |
| Year | 2019 |
| Title | LncRNA GAPLINC promotes the growth and metastasis of glioblastoma by sponging miR-331-3p |
External Links
| Links for GAPLINC | GenBank HGNC NONCODE |
| Links for glioblastoma multiforme | OMIM COSMIC |